GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
  • Education
    • Master Theses
    • PhD Theses
  • Services
Home / Archives for Boucher CA

State of the antiretroviral therapy in human immunodeficiency virus drug resistance: Science and technology knowledge gap

  • Autores: Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM
  • Ano de Publicação: 2018
  • Journal: AIDS Reviews
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/29628515

Abstract Resistance to antiretroviral therapy (ART) threatens the efficacy of human immunodeficiency virus type 1 (HIV-1) treatment. We present a review of knowledge gaps in the science and technologies of acquired HIV-1 drug resistance (HIVDR) in an effort to facilitate research, scientific exchange, and progress in clinical management. The expert authorship of this review convened […]
Ler mais

State of the antiretroviral therapy in human immunodeficiency virus drug resistance: Surveillance and regional gaps

  • Autores: Boucher CA, Bobkova MR, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Vandamme AM, Dorr P
  • Ano de Publicação: 2018
  • Journal: AIDS Reviews
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/29628514

Abstract This article is the second of a two-part review aiming to identify gaps in the knowledge and management of human immunodeficiency virus type 1 drug resistance (HIVDR) from global and regional perspectives. Here, we examine the policy and programmatic gaps in HIVDR surveillance, the affected populations and settings, and implications for clinical practice. The […]
Ler mais

Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time

  • Autores: Assel M, Boucher CA, De Luca A, Fabbiani M, Frentz D, Incardona F, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Van de Vijver DA, Zazzi M, Libin P, Vandamme AM, Van Laethem K
  • Journal: PLoS One
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Comparison+of+HIV-1+Genotypic+Resistance+Test+Interpretation+Systems+in+Predicting+Virological+Outcomes+Over+Time

BACKGROUND: Several decision support systems have been developed to interpret HIV-1 drug resistance genotyping results. This study compares the ability of the most commonly used systems (ANRS, Rega, and Stanford’s HIVdb) to predict virological outcome at 12, 24, and 48 weeks. METHODOLOGY/PRINCIPAL FINDINGS: Included were 3763 treatment-change episodes (TCEs) for which a HIV-1 genotype was […]
Ler mais

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

  • Autores: Altmann A, Boucher CA, Brun-Vezinet F, Harrigan PR, Incardona F, Kaiser R, Lengauer T, Morris L, Obermeier M, Peres Y, Perno CF, Petroczi A, Phanuphak P, Pillay D, Prosperi M, Rosen-Zvi M, Schülter E, Shafer RW, Sönnerborg A, Struck D, Wensing AMJ, Zazzi M, Vandamme AM, Van Laethem K
  • Journal: HIV Medicine
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Prediction+of+response+to+antiretroviral+therapy+by+human+experts+and+by+the+EuResist+data-driven+expert+system+(the+EVE+study).

OBJECTIVES:
The EuResist expert system is a novel data-driven online system for computing the probability of 8-week success for any given pair of HIV-1 genotype and combination antiretroviral therapy regimen plus optional patient information. The objective of this study was to compare the EuResist system vs. human experts (EVE) for the ability to predict response to treatment.
Ler mais

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

  • Autores: Albert J, Åsjö B, Balotta C, Boucher CA, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Deforche K, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Libin P, Liitsola K, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Schmit JC, Schuurman R, Sönnerborg A, SPREAD-programme, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DA, Van Laethem K, Vandamme AM, Vercauteren J, Wensing AMJ
  • Journal: Retrovirology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Treatment-associated+polymorphisms+in+protease+are+significantly+associated+with+higher+viral+load+and+lower+CD4+count+in+newly+diagnosed+drug-naive+HIV-1+infected+patients

BACKGROUND:
The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore are expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission.
Ler mais

  • 1
  • 2
  • Next Page »

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013